Proton magnetic resonance spectroscopy (1H-MRS) for the diagnosis of brain tumors and the evaluation of treatment;Apport de la spectroscopie 1H au diagnostic des processus tumoraux intra-parenchymateux cérébraux et à leur suivi thérapeutique

Neurochirurgie

Volumn 51, Issue 3-4 II, 2005, Pages 299-308

  Grand, S ^a   Tropres, I ^b   Hoffmann, D ^a   Ziegler, A ^c   Le Bas, J F ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

^c INSERM   (France)

Author keywords

Brain tumors; Diagnosis; Prognosis; Proton magnetic resonance spectroscopy; Therapeutic response

Indexed keywords

AMINO ACID; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; LACTIC ACID; LIPID; ACETIC ACID DERIVATIVE; ALANINE; DIAGNOSTIC AGENT; INOSITOL; LACTIC ACID DERIVATIVE; PHOSPHOLIPID; PROTON;

BRAIN ABSCESS; BRAIN TUMOR; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FOLLOW UP; GLIOSIS; HISTOLOGY; HUMAN; IMAGE ANALYSIS; METABOLITE; METASTASIS; NEUROIMAGING; OLIGODENDROGLIOMA; PATIENT MONITORING; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; ARTICLE; CANCER INVASION; EVALUATION; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; TIME;

ACETATES; ALANINE; AMINO ACIDS; BRAIN NEOPLASMS; CHOLINE; CREATINE; DIAGNOSIS, DIFFERENTIAL; GLUTAMIC ACID; GLUTAMINE; HUMANS; INOSITOL; LACTATES; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASM INVASIVENESS; OLIGODENDROGLIOMA; PHOSPHOLIPIDS; PROTONS; TIME FACTORS;

EID: 25844435670     PISSN: 00283770     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0028-3770(05)83491-5     Document Type: Conference Paper

References (42)

1. AUER DP, GOSSL C, SCHIRMER T, CZISCH M. Improved analysis of 1H-MR spectra in the presence of mobile lipids. Magn Reson Med 2001; 46: 615-618.
2. CASTILLO M, SMITH JK, KWOCK L. Correlation of myoinositol levels and grading of cerebral astrocytomas. Am J Neuroradiol 2000; 21: 1645-1649.
3. DE EDELENYI FS, RUBIN C, ESTEVE F, et al. A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images. Nat Med 2000; 6: 1287-1289.
4. DE STEFANO N, CARAMANOS Z, PREUL MC, FRANCIS G, ANTEL JP, ARNOLD DL. In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging. Ann Neurol 1998; 44: 273-278.
5. DUCREUX D, WU RH, MIKULIS DJ, BRUGGE K. Diffusion-weighted imaging and single-voxel MR spectroscopy in a case of malignant cerebral lymphoma. Neuroradiology 2003; 45: 865-868.
6. ESTEVE F, GRAND S, RUBIN C, et al. MR spectroscopy of bilateral thalamic gliomas. Am J Neuroradiol 1999; 20: 876-881.
7. ESTEVE F, RUBIN C, GRAND S, KOLODIE H, LE BAS JF. Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy. Int J Radiat Oncol Biol Phys 1998; 40: 279-286.
8. GALANAUD D, CHINOT O, NICOLI F, et al. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg 2003; 98: 269-276.
9. GIRARD N, WANG ZJ, ERBETTA A, et al. Prognostic value of proton MR spectroscopy of cerebral hemisphere tumors in children. Neuroradiology 1998; 40: 121-125.
10. GRAND S, PASSARO G, ZIEGLER A, et al. Necrotic tumor versus brain abscess: importance of amino acids detected at 1H MR spectroscopy. Initial results. Radiology 1999; 213: 785-793.
11. GRAVES EE, NELSON SJ, VIGNERON DB, et al. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. Am J Neuroradiol 2001; 22: 613-624.
12. HALL WA, MARTIN A, LIU H, TRUWIT CL. Improving diagnostic yield in brain biopsy: coupling spectroscopic targeting with real-time needle placement. J Magn Reson Imaging 2001; 13: 12-15.
13. HARTING I, HARTMANN M, JOST G, et al. Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett 2003; 342: 163-166.
14. HEESTERS MA, KAMMAN RL, MOOYAART EL, GO KG. Localized proton spectroscopy of inoperable brain gliomas. Response to radiation therapy. J Neurooncol 1993; 17: 27-35.
15. HERMINGHAUS S, DIERKS T, PILATUS U, et al. Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J Neurosurg 2003; 98: 74-81.
16. HERMINGHAUS S, PILATUS U, MOLLER-HARTMANN W, et al. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 2002; 15: 385-392.
17. HOWE FA, BARTON SJ, CUDLIP SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003; 49: 223-232.
18. KROUWER HG, KIM TA, RAND SD, et al. Single-voxel proton MR spectroscopy of nonneoplastic brain lesions suggestive of a neoplasm. Am J Neuroradiol 1998; 19: 1695-1703.
19. KUZNETSOV YE, CARAMANOS Z, ANTEL SB, et al. Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery 2003; 53: 565-574.
20. LAW M, CHA S, KNOPP EA, JOHNSON G, ARNETT J, LITT AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002; 222: 715-721.
21. LONDONO A, CASTILLO M, ARMAO D, KWOCK L, SUZUKI K. Unusual MR spectroscopic imaging pattern of an astrocytoma: lack of elevated choline and high myo-inositol and glycine levels. Am J Neuroradiol 2003; 24: 942-945.
22. MAJOS C, ALONSO J, AGUILERA C, et al. Proton magnetic resonance spectroscopy ((1)H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol 2003; 13: 582-591.
23. MARTIN AJ, LIU H, HALL WA, TRUWIT CL. Preliminary assessment of turbo spectroscopic imaging for targeting in brain biopsy. Am J Neuroradiol 2001; 22: 959-968.
24. MOLLER-HARTMANN W, HERMINGHAUS S, KRINGS T, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002; 44: 371-381.
25. NEGENDANK WG, SAUTER R, BROWN TR, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 1996; 84: 449-458.
26. NELSON SJ, VIGNERON DB, DILLON WP. Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. NMR Biomed 1999; 12: 123-138.
27. OTT D, HENNIG J, ERNST T. Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology 1993; 186: 745-752.
28. POPTANI H, KAARTINEN J, GUPTA RK, NIEMITZ M, HILTUNEN Y, KAUPPINEN RA. Diagnostic assessment of brain tumours and non-neoplastic brain disorders in vivo using proton nuclear magnetic resonance spectroscopy and artificial neural networks. J Cancer Res Clin Oncol 1999; 125: 343-349.
29. PREUL MC, CARAMANOS Z, LEBLANC R, VILLEMURE JG, ARNOLD DL. Using pattern analysis of in vivo proton MRSI data to improve the diagnosis and surgical management of patients with brain tumors. NMR Biomed 1998; 11: 192-200.
30. PREUL MC, CARAMANOS Z, VILLEMURE JG, et al. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 2000; 46: 306-318.
31. RIJPKEMA M, SCHUURING J, VAN DER MEULEN Y, et al. Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 2003; 16: 12-18.
32. SHIMIZU H, KUMABE T, SHIRANE R, YOSHIMOTO T. Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. Am J Neuroradiol 2000; 21: 659-665.
33. SHIMIZU H, KUMABE T, TOMINAGA T, et al. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. Am J Neuroradiol 1996; 17: 737-747.
34. SIJENS PE, VECHT CJ, LEVENDAG PC, VAN DIJK P, OUDKERK M. Hydrogen magnetic resonance spectroscopy follow-up after radiation therapy of human brain cancer. Unexpected inverse correlation between the changes in tumor choline level and post-gadolinium magnetic resonance imaging contrast. Invest Radiol 1995; 30: 738-744.
35. SMITH JK, CASTILLO M, KWOCK L. MR spectroscopy of brain tumors. Magn Reson Imaging Clin N Am 2003; 11: 415-429.
36. SMITH JK, KWOCK L, CASTILLO M. Effects of contrast material on single-volume proton MR spectroscopy. Am J Neuroradiol 2000; 21: 1084-1089.
37. TATE AR, MAJOS C, MORENO A, HOWE FA, GRIFFITHS JR, ARUS C. Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study. Magn Reson Med 2003; 49: 29-36.
38. TEDESCHI G, LUNDBOM N, RAMAN R, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997; 87: 516-524.
39. TZIKA AA, ASTRAKAS LG, ZARIFI MK, et al. Spectroscopic and perfusion magnetic resonance imaging predictors of progression in pediatric brain tumors. Cancer 2004; 100: 1246-1256.
40. USENIUS T, USENIUS JP, TENHUNEN M, et al. Radiation-induced changes in human brain metabolites as studied by 1H nuclear magnetic resonance spectroscopy in vivo. Int J Radiat Oncol Biol Phys 1995; 33: 719-724.
41. VAN TASSEL P, BRUNER JM, MAOR MH, et al. MR of toxic effects of accelerated fractionation radiation therapy and carboplatin chemotherapy for malignant gliomas. Am J Neuroradiol 1995; 16: 715-726.
42. ZIEGLER A, VON KIENLIN M, DECORPS M, REMY C. High glycolytic activity in rat glioma demonstrated in vivo by correlation peak 1H magnetic resonance imaging. Cancer Res 2001; 61: 5595-5600.